Ozempic and Hair Loss: Will Your Hair Grow Back?

Does Ozempic cause hair loss?

There is evidence of an association between semaglutide treatment and hair loss. The uncertainty concerns how much comes from weight loss and nutritional changes, and whether the medicine has an additional effect of its own. The available studies have not established one mechanism that explains every case.^[6]

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. Ozempic is used in adults with type 2 diabetes, including certain patients with cardiovascular or kidney disease. Wegovy has a different treatment program and includes weight-management indications. Their study populations and doses differ.^[1,2]

Mounjaro and Zepbound contain tirzepatide, which acts on both GIP and GLP-1 receptors. The Zepbound figures below come from weight-management trials. They should not be used as an estimate for someone taking Mounjaro in a different clinical setting.^[3]

What the product information reports

Both Wegovy and Zepbound product information describe these events as associated with weight reduction.^[2,3] The two Wegovy datasets happen to report the same percentage at 2.4 mg, but they are separate study populations. Comparisons between different medicines' trials cannot establish which drug is safest for an individual's hair.

The Zepbound figures are worth reading closely. If hair loss were a direct, dose-driven effect on follicles, a higher dose would be expected to produce more of it, as the Wegovy figures appear to. Across the three tirzepatide doses the rate stays at 4–5%. That does not exclude a drug effect, but it suggests that dose alone does not decide who sheds.^[3]

Does the Wegovy 3.3% figure apply to Ozempic?

No. The figure is often quoted as if it described Ozempic users, but it comes from Wegovy 2.4 mg weight-management studies. Ozempic’s prescribing information gives no equivalent controlled rate for people treated for type 2 diabetes.^[1,2] The Gupta review also found that semaglutide doses below 2 mg weekly were rarely implicated, while the higher doses used to treat obesity were more commonly associated with hair loss.^[6]

What the research reviews add

Cheng and Chang's 2026 meta-analysis included nine interventional studies and 4,114 GLP-1 users. It found a pooled risk ratio of 3.25, with a 95% confidence interval of 1.44–7.36, compared with placebo. A separate analysis estimated that hair loss occurred in 3.9% of treated participants. The relative comparison and the event percentage answer different questions.^[4]

Viquez Burboa and colleagues included 17 studies encompassing 1,091,743 patient-exposures in their review. Their pooled odds ratio of 1.40, with a 95% confidence interval of 1.33–1.48, came specifically from three cohort studies. It describes an association with non-scarring alopecia; it does not mean that 40% of users lost their hair.^[5]

Adverse-event reporting points the same way. Analyzing FDA Adverse Event Reporting System data from 2022 to 2023, Godfrey and colleagues found disproportionate alopecia reporting for semaglutide (reporting odds ratio 2.46; 95% CI 2.14–2.83) and tirzepatide (1.73; 1.42–2.09). A reporting odds ratio detects a signal; it cannot tell us what percentage of users will lose hair.^[15]

These findings strengthen the evidence that the complaint deserves attention. However, many reports do not establish the precise hair-loss diagnosis, and observational data cannot fully account for differences in nutrition or pre-existing thinning. Current evidence does not support a dependable ranking of GLP-1 medicines by hair-loss risk.^[6]

Why weight loss can trigger shedding

Telogen effluvium is widespread shedding caused by a disturbance in the hair-growth cycle. A physiological stress can cause more follicles than usual to leave active growth. The affected hairs stay in the scalp for a while before being released, which explains the delay between the trigger and the shedding.^[8]

Major weight loss can trigger this process without any GLP-1 medication. The American Academy of Dermatology lists losing 20 pounds (roughly 9 kg) or more among the stressors that can bring on excessive shedding.^[7] Low protein intake and iron deficiency are also recognized contributors. During semaglutide treatment, appetite suppression may make it difficult to maintain adequate food intake. Persistent nausea can make that harder still.^[6,8]

For some people, the relevant change begins early in treatment, when meals become much smaller. The total amount eventually lost on the scales may not explain when the hair cycle was first disrupted.

In this article, shedding means hairs being released from the scalp. Thinning describes the loss of visible coverage. A person can notice both, but the appearance alone does not identify the cause. The medical term alopecia includes several different hair-loss conditions.

When does shedding start, and how long does recovery take?

Telogen effluvium often becomes noticeable about three months after a trigger, although the interval can range from one to six months.^[8] The first injection is not necessarily the starting point: an illness during treatment or a later period of poor food intake may be more relevant.

The American Academy of Dermatology describes a return toward normal fullness over roughly six to nine months as the body readjusts. Severe or prolonged episodes can take a year or longer to recover cosmetically. These are general expectations for telogen effluvium; there is no established Ozempic-specific timetable measured from the first dose.^[7,8]

You may therefore see fewer hairs in the shower while your part still looks wide. That can happen because the returning hairs are still short. If density continues to deteriorate, or a clear pattern of thinning remains, the diagnosis should be reviewed.

What to do if your hair starts shedding

Start with the history of the change. An assessment is more useful when it includes what happened in the months before the shedding began.

Review your medication and weight-loss timeline

Write down when treatment started and when the dose changed. Add approximate weight changes and any period when eating became difficult. Mention recent illness or surgery, even if you had recovered before the hair started shedding.

Take this information to the clinician managing your diabetes or weight treatment. Do not stop or reduce prescribed medication on your own because of hair shedding. The decision needs to account for the medicine's benefits and the possible causes of the hair change.^[5]

Check whether you are eating enough

Appetite suppression can make an inadequate diet feel quite comfortable. Review what you actually eat over several days, including your protein sources. If nausea or vomiting prevents regular meals, tell your prescriber.

A clinician or dietitian can help adjust intake to your health needs while maintaining an appropriate weight-management plan. There is no established diet that specifically prevents Ozempic-related hair loss. Deliberately regaining weight is not an evidence-based treatment for it. The aim is to address nutritional stress and any identified deficiency.^[8]

Investigate additional causes when the history warrants it

Blood tests are selected according to symptoms and medical history. They may include a complete blood count and iron studies, including ferritin. Thyroid testing is appropriate when a thyroid disorder is suspected; further micronutrient testing depends on the diet and clinical findings. Normal blood results do not exclude telogen effluvium or pattern hair loss.^[8]

Avoid automatically adding a high-dose hair supplement. Evidence for biotin improving hair in people without deficiency is limited, and high doses can interfere with laboratory tests. Tell the clinician and laboratory which supplements you take.^[9]

Keep normal washing and gentle hair care

Washing releases hairs that are already ready to shed. It does not cause healthy follicles to enter telogen effluvium, and avoiding shampoo will not keep those hairs growing. Gentle handling can also reduce breakage while coverage is lower.

Healthy scalps commonly shed around 50–100 hairs a day, but this is a rough reference, not a target to monitor. A clear change from your usual shedding is more useful to discuss than a single day's count.^[7]

Does minoxidil help?

Minoxidil may be considered when androgenetic alopecia is also present. Uncomplicated acute telogen effluvium often recovers after the trigger has been addressed, so treatment should follow the diagnosis.^[8]

Topical minoxidil can temporarily increase shedding when it is started. A small 2025 retrospective study of 49 patients with androgenetic alopecia recorded an increase during the first 12 weeks. That finding concerns starting minoxidil; it is not evidence that minoxidil prevents semaglutide-associated shedding.^[10]

Telogen effluvium and pattern hair loss

Temporary shedding can make previously subtle pattern hair loss easier to see. When surrounding coverage falls, a receding frontal area or widening part may suddenly look much more pronounced. Both conditions can occur in the same person.^[7]

The table describes typical patterns. A photograph of a wider part cannot reliably distinguish between them. Examination, sometimes with trichoscopy, helps interpret the change.^[6,8]

Short hairs also need careful interpretation. They may represent early regrowth, while fine hairs of different diameters can suggest miniaturization. The surrounding pattern and changes over time help the clinician decide what those findings mean.

When should you have your scalp examined?

Arrange an assessment if shedding is substantial, continues to worsen or is difficult to explain. Persistent shedding beyond six months deserves another review, but you do not need to wait that long to seek help.^[8]

Seek earlier evaluation for sharply defined bald patches, significant scalp pain or inflammation. Marked scaling, areas that appear scarred, or unexpected eyebrow and eyelash loss also warrant examination. These findings can point toward conditions that need a different approach.^[8]

Bring older photographs if you have them. They can help establish whether a frontal pattern or widening part was already developing before treatment began.

Can you have a hair transplant after Ozempic-related shedding?

Hair transplantation does not treat active telogen effluvium. It may be considered later if permanent hair loss remains and the donor area is suitable.^[8,14]

Why temporary shedding can change the graft estimate

At Pure Line, recent diffuse shedding affects how we interpret an assessment. A scalp photographed during its lowest point in density can appear to need more transplanted hair than it will after native regrowth.

The donor area needs the same consideration. Widespread shedding can temporarily change its appearance, making one examination less representative of its usual density.

This creates a practical planning problem: the apparent recipient area can look larger while the donor appears weaker. We want to understand how much of that picture is temporary before deciding where grafts would be useful.

Follow-up gives us a chance to assess recovery and examine the remaining pattern of miniaturization. If native hairs restore enough coverage, the proposed recipient area or graft estimate may change. Donor follicles are limited, so that information matters to the patient's longer-term options.

What we look for before finalizing a plan

We look for active shedding to be settling and for successive assessments to show that density is becoming stable. We also consider whether an ongoing nutritional or medical problem still needs attention. Any remaining pattern hair loss must be clear enough to plan around.

There is no universally established waiting period for surgery after GLP-1-associated shedding. A review at six months can be useful, but continuing changes in density may justify further observation. The elapsed time alone does not establish suitability.

Before traveling to Istanbul

If you are considering treatment at Pure Line, mention recent shedding during the initial consultation. Share photographs from before the change if available, alongside current views of the scalp and donor area. Include your GLP-1 medication and dose in the medical history.

A remote assessment can identify reasons to investigate further or wait before booking surgery. Photographs have limits, and the final donor assessment and surgical plan require an in-person examination. Discussing the shedding before arranging travel gives time for any local medical evaluation that may be needed.

Semaglutide and anesthesia planning

GLP-1 medicines can delay stomach emptying. Retained stomach contents can increase aspiration risk during general anesthesia or deep sedation. Hair transplantation usually uses local anesthesia, but sedation may be added, so the surgical team needs to know about the medication before the procedure.^[1]

Current US multi-society guidance allows most patients to keep taking GLP-1 medication before surgery. The prescriber and anesthesia team should agree on the plan for an individual patient. Dose escalation and significant gastrointestinal symptoms can change that assessment.^[11]

Depending on the circumstances, the team may prescribe a liquid-only diet before the procedure or use gastric ultrasound. Some procedures need to be postponed. Follow the instructions provided for your own treatment; do not independently change your medication or fasting schedule.^[11]

Shedding after a transplant

Transplanted hair shafts commonly shed during early recovery while the follicles remain in place. Nearby native hairs can also shed after surgery, often called shock loss. Miniaturized native hairs may have less predictable recovery.^[12]

If shedding occurs after a transplant, contact the team that performed it with the dates and photographs. The surgical recovery phase should be considered alongside your earlier hair-loss history; timing alone cannot establish the cause.

How the evidence was used

This article is a clinical overview. Trial percentages come from the product information or the cited research and retain their study context. Spontaneous adverse-event reports are used to discuss safety signals, without calculating an incidence rate from them.

Recovery expectations draw on general telogen effluvium guidance. The transplant-planning discussion applies that background to clinical assessment and does not claim a validated waiting period specific to semaglutide.

The sources below were checked for this revision on September 14, 2026.

Frequently asked questions

— Dr. Mesut Demir